Unibio strengthens its organisation with the appointment of Jakob Brix Christensen as Group CFO in Unibio Group. Jakob Brix Christensen will take up the position as Group CFO on 1 May 2018, and his key tasks will be to strengthen the finance function for Unibio’s further expansion as well as strategic sparring with Henrik Busch-Larsen, CEO and the largest shareholder in Unibio.
Jakob Brix Christensen will be part of top management in a modern biotech company experiencing rapid development. Unibio has developed a fermentation technology for the production of bacterial protein, the U-Loop® fermentor, converting methane into granules of highly concentrated protein, Uniprotein®, which can be used as a sustainable alternative to for instance fishmeal in animal feed. Unibio is now only weeks away from launching production at its first large-scale plant in cooperation with a customer investing a two-digit million amount in the project.
Jakob Brix Christensen has almost 15 years of experience from international life science companies as well as ten years of experience as a financial adviser and accountant from Handelsbanken Capital Markets and Ernst & Young. Jakob comes from a position as CFO in the listed biotech company BioPorto A/S. Before that Jakob was part of the management team of Novozymes Biopharma (now Albumedix A/S) and investor relations manager and US CFO at Origio A/S.
“I see Unibio as a very exciting company with a unique technology allowing a bacterial fermentation process to convert methane into a natural protein product with a high biological value which can at first be used for animal feed. In a world where many megatrends point to a growing lack of protein-rich animal feed, I am convinced that Unibio will play a decisive role going forward. I look forward to becoming part of Unibio and contributing to the continued development and value creation in the company”, Jakob says.
Jakob holds an MSc in strategy and management and a Graduate Diploma in Business Administration (financial and management accounting) from Aarhus University, School of Business and Social Sciences, supplemented by management training from the University of Richmond, Virginia, USA.
Unibio CEO Henrik Busch-Larsen states: “It has been an exciting process to get to know Jakob. He brings a lot of experience from the capital markets and listed companies into Unibio. The chemistry between us is really good, which is, of course, an important precondition for successful cooperation. A big welcome on board to Jakob.”